PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income ($18.6) million.
“Total revenue for the three months ended March 31, 2026 was $0.4 million, including both capital and disposable sales. Total GAAP costs and expenses, representing cost of product revenue, research and development, and selling, general and administrative expenses, for the three months ended March 31, 2026, were $19.6 million, an increase of $1.6 million compared to $18.0 million in the prior year period. The increase was primarily driven by increased investment in clinical programs, partially offset by lower stock-based compensation expense. Non-GAAP costs and expenses for the three months ended March 31, 2026, were $17.4 million, an increase of $4.7 million compared to $12.7 million in the prior year period. GAAP net loss for the three months ended March 31, 2026 was ($18.6) million compared to ($16.8) million for the three months ended March 31, 2025. Non-GAAP net loss for the three months ended March 31, 2026 was ($16.4) million compared to ($11.4) million for the three months ended”
Material Agreements
PULSE BIOSCIENCES, INC. terminated Prior Distribution Agreement with the sales agents named therein valued at up to $59,976,196 (effective 2026-02-18).
“Prior to the Company’s entry into the Sales Agreement, on February 18, 2026, the Company terminated its at-the-market offering program in accordance with the terms of its prior equity distribution agreement, dated as of July 15, 2024 (the “Prior Distribution Agreement”), between the Company and the sales agents named therein.”
Material Agreements
PULSE BIOSCIENCES, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $59,976,196 (effective 2026-02-19).
“On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through TD Cowen shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $59,976,196 (the “Shares”).”
Jon Skinner was appointed as Chief Financial Officer at PULSE BIOSCIENCES, INC..
“Pulse Biosciences, Inc. (the “Company”) has appointed Jon Skinner as Chief Financial Officer of the Company, effective as of February 3, 2025”
Paul A. LaViolette was appointed as Chief Executive Officer and President at PULSE BIOSCIENCES, INC..
“The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025”
Robert W. Duggan was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
“the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board”
Paul A. LaViolette was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
“the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board”
Paul A. LaViolette was elected as Director at PULSE BIOSCIENCES, INC..
“the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors”
Shelley D. Spray departed as Director at PULSE BIOSCIENCES, INC..
“Director Shelley D. Spray did not stand for reelection at the Annual Meeting.”
Kevin P. Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..
“Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date”
Burke T. Barrett was appointed as Director at PULSE BIOSCIENCES, INC..
“The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024”
Burke T. Barrett was appointed as President and Chief Executive Officer at PULSE BIOSCIENCES, INC..
“The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024”
Earnings Releases
PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2024 results: net income GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon.
“Pulse Biosciences, Inc. (the "Company") announced its financial and operational results for the fiscal quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.